Bliss GVS Pharma Reports Mixed Q4 Results Amid Improved Liquidity and Debt Management

Bliss GVS Pharma has recently reported its financial results for the quarter ending December 2024, revealing a complex picture of its performance. The company has experienced a revision in its evaluation, with the score adjusting to -7 from -14 over the past three months.
On a positive note, Bliss GVS Pharma has demonstrated a strong ability to manage interest payments, with its operating profit to interest ratio reaching its highest level in the last five quarters at 27.58 times. Additionally, the company has successfully reduced its debt-equity ratio to 0.09 times, indicating a decrease in borrowing relative to equity capital. Furthermore, cash and cash equivalents have reached Rs 219.84 crore, marking the highest level in the last six half-yearly periods, suggesting an improvement in short-term liquidity.

Conversely, the financial results also highlight challenges for Bliss GVS Pharma. The profit before tax has shown a significant decline year on year, while the profit after tax has also decreased. The operating profit margin has reached its lowest point in five quarters, indicating a decline in efficiency. Moreover, the company's reliance on non-operating income has increased, raising concerns about the sustainability of its business model.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.